# ADULT MEDICATION GUIDELINE

## Ondansetron

<table>
<thead>
<tr>
<th>Scope (Staff):</th>
<th>All WNHS Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope (Area):</td>
<td>Obstetrics and Gynaecology</td>
</tr>
</tbody>
</table>

This document should be read in conjunction with the [Disclaimer](#).

## Quick Links

<table>
<thead>
<tr>
<th>Dose</th>
<th>Administration</th>
<th>Monitoring</th>
<th>Pregnancy and Breastfeeding</th>
</tr>
</thead>
</table>

## Restrictions

- **Formulary:** Unrestricted

## Medication Class

5HT₃ antagonist

## Presentation

- **Wafer:** 4mg, 8mg
- **Tablet:** 4mg
- **Ampoule:** 4mg/2mL

## Storage

- **Wafer and tablet:** Store at room temperature, below 30°C.
- **Ampoule:** Store at room temperature, below 25°C. Protect from light.

## Dose

**Nausea and Vomiting in Pregnancy / Hyperemesis Gravidarum (fourth line)**

**Oral/IV:**

4–8mg every 12 hours when required. Maximum 16mg in 24 hours.

**Post-Operative Nausea and Vomiting (PONV)**

**Oral/IV:**
4mg every 6 hours when required. Maximum 20mg in 24 hours.

**Mild Pruritus as a Side Effect of Epidural Opioids**

**Oral/IV**

4mg every 6 hours when required.

**Note**: Reduce maximum dose to 8mg in patients with severe hepatic impairment or in patients above 75 years of age.

**Administration**

**Oral - Wafer**

Place on top of the tongue to dissolve and then swallow.

**IV Injection (for doses up to 8mg)**

**Administration**: Inject SLOWLY over at least 30 seconds and preferably over 3 to 5 minutes.

**IV Infusion (for doses above 8mg up to 16mg and for all doses in patients > 75 years)**

**Step 1 Dilution**: Dilute with 50mL of Sodium chloride 0.9% or Glucose 5%.

**Step 2 Administration**: Infuse over at least 15 minutes.

**Pregnancy**

1st Trimester: Consider alternative

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact KEMH Obstetric Medicines Information Service.

**Breastfeeding**

Considered safe to use

**Related Policies, Procedures & Guidelines**
## References


---

<table>
<thead>
<tr>
<th>Keywords</th>
<th>Ondansetron, hyperemesis gravidarum, post-operative nausea, vomiting, PONV, zofran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner:</td>
<td>Chief Pharmacist</td>
</tr>
<tr>
<td>Author/ Reviewer</td>
<td>KEMH Pharmacy Department</td>
</tr>
<tr>
<td>Version Info:</td>
<td>4.0</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>03/2014</td>
</tr>
<tr>
<td>Last Reviewed:</td>
<td>02/11/2021</td>
</tr>
<tr>
<td>Review Date:</td>
<td>Nov 2024</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Medicines and Therapeutics Committee</td>
</tr>
<tr>
<td>Date:</td>
<td>02/11/2021</td>
</tr>
</tbody>
</table>

NSQHS Standards Applicable:
- [x] Std 1: Clinical Governance
- [ ] Std 2: Partnering with Consumers
- [ ] Std 3: Preventing and Controlling Healthcare Associated Infection
- [ ] Std 4: Medication Safety
- [ ] Std 5: Comprehensive Care
- [ ] Std 6: Communicating for Safety
- [ ] Std 7: Blood Management
- [ ] Std 8: Recognising and Responding to Acute Deterioration

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.
The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.